New Parkinson's pill enters first human safety tests
NCT ID NCT07310264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether an experimental oral drug called AX-5006 is safe and tolerable in healthy adults and people with Parkinson's disease. The study involves 84 participants across three parts: single doses in healthy volunteers, multiple daily doses in healthy volunteers, and 28 days of daily dosing in Parkinson's patients. Researchers will monitor side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AX-5006 (also called VT-5006), an oral drug
What this could lead to
If safe and well-tolerated, this could pave the way for larger studies to see if AX-5006 helps control Parkinson's symptoms.
What could go wrong
This is a very early, first-in-human trial focused only on safety, not effectiveness. The drug may not work for Parkinson's or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Human Drug Research
RECRUITINGLeiden, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••